Zacks Research Has Positive Opinion of WST FY2026 Earnings

West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) – Investment analysts at Zacks Research boosted their FY2026 earnings per share estimates for shares of West Pharmaceutical Services in a report released on Thursday, November 19th. Zacks Research analyst Team now expects that the medical instruments supplier will post earnings per share of $9.41 for the year, up from their prior estimate of $8.88. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $9.44 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ Q4 2026 earnings at $2.25 EPS, Q1 2027 earnings at $2.29 EPS, Q2 2027 earnings at $2.54 EPS, Q3 2027 earnings at $2.64 EPS, Q4 2027 earnings at $2.67 EPS, Q1 2028 earnings at $2.61 EPS, Q2 2028 earnings at $3.02 EPS, Q3 2028 earnings at $2.82 EPS and FY2028 earnings at $11.46 EPS.

West Pharmaceutical Services (NYSE:WST – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.20 by $0.46. The company had revenue of $874.50 million for the quarter, compared to the consensus estimate of $827.12 million. West Pharmaceutical Services had a net margin of 18.81% and a return on equity of 21.78%. West Pharmaceutical Services’s revenue was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.96 earnings per share.

A number of other equities research analysts also recently weighed in on WST. Jefferies Financial Group reaffirmed a “buy” rating and set a $475.00 price objective on shares of West Pharmaceutical Services in a research report on Monday, November 2nd. Weiss Ratings raised West Pharmaceutical Services from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, November 2nd. Morgan Stanley upgraded West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $365.00 to $400.00 in a research note on Tuesday, September 22nd. UBS Group upped their price objective on shares of West Pharmaceutical Services from $340.00 to $415.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. Finally, Barclays increased their price objective on shares of West Pharmaceutical Services from $440.00 to $500.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Thirteen research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $424.67.

Read Our Latest Analysis on WST

West Pharmaceutical Services Stock Down 1.6%

NYSE:WST opened at $390.36 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.10. West Pharmaceutical Services has a 1-year low of $223.83 and a 1-year high of $438.27. The company has a 50-day moving average of $386.67 and a 200 day moving average of $325.12. The firm has a market cap of $27.19 billion, a PE ratio of 43.81, a price-to-earnings-growth ratio of 2.37 and a beta of 1.13.

West Pharmaceutical Services Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, November 18th. Investors of record on Wednesday, November 11th were issued a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a dividend yield of 0.3%. This is a boost from West Pharmaceutical Services’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend was Tuesday, November 10th. West Pharmaceutical Services’s dividend payout ratio is 11.67%.

Insider Activity

In other West Pharmaceutical Services news, VP Annette Favorite sold 8,135 shares of the company’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $340.81, for a total value of $2,772,489.35. Following the sale, the vice president directly owned 16,845 shares of the company’s stock, valued at approximately $5,740,944.45. This represents a 32.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 15,659 shares of company stock worth $5,443,749 over the last three months. Company insiders own 0.60% of the company’s stock.

Hedge Funds Weigh In On West Pharmaceutical Services

Institutional investors and hedge funds have recently modified their holdings of the stock. American Century Companies Inc. raised its stake in West Pharmaceutical Services by 12.3% during the 3rd quarter. American Century Companies Inc. now owns 111,760 shares of the medical instruments supplier’s stock worth $41,436,000 after acquiring an additional 12,203 shares in the last quarter. Cim Investment Management Inc. purchased a new position in shares of West Pharmaceutical Services in the 3rd quarter valued at approximately $639,000. Kestra Advisory Services LLC acquired a new position in shares of West Pharmaceutical Services in the third quarter valued at approximately $365,000. Innovator Capital Management LLC acquired a new position in shares of West Pharmaceutical Services in the third quarter valued at approximately $1,449,000. Finally, Coastal Bridge Advisors LLC purchased a new stake in shares of West Pharmaceutical Services during the third quarter worth approximately $767,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

Key Stories Impacting West Pharmaceutical Services

Here are a few of the latest stories about WST:

  • Positive Sentiment: Zacks also increased estimates for multiple quarters through 2028, including Q3 2028 to $2.82 from $2.69 and Q2 2028 to $3.02 from $2.83. Broad upward revisions could support sentiment toward WST.
  • Neutral Sentiment: Zacks maintained a “Hold” rating, tempering the signal from its higher earnings forecasts.
  • Negative Sentiment: A recent Zacks analysis cited near-term headwinds, despite longer-term support from high-value product demand, biologics exposure and regulatory upgrades. Article: Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

West Pharmaceutical Services Company Profile

(Get Free Report)

West Pharmaceutical Services designs and manufactures packaging components and delivery systems used by the pharmaceutical, biotechnology, and medical device industries. Its products help contain and administer injectable medicines and include elastomeric components, such as stoppers and seals, as well as syringe components and other packaging and delivery solutions. The company also provides contract manufacturing services for medical devices and pharmaceutical delivery systems. Its customers include companies developing and producing branded, generic, and biologic medicines.

Recommended Stories

Earnings History and Estimates for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.